Phibro Animal Health To Develop, Commercialize Lighthouse Pharma's Proprietary Compound For Canine Periodontal Care Under Signed Licensing Agreement

TEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (NASDAQ:PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals.

This agreement grants Phibro exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma's proprietary compound for canine periodontal care. The compound represents a promising advancement in veterinary dental health, addressing a widespread and often under-treated condition in dogs.